Delcath Systems, Inc. (NASDAQ:DCTH) Short Interest Update
Delcath Systems, Inc. (NASDAQ:DCTH) saw a significant increase in short interest in July. As of July 14th, there was short interest totalling 32,294,368 shares, an increase of 41.0% from the June 30th total of 22,896,470 shares. Based on an average trading volume of 72,471,463 shares, the days-to-cover ratio is currently 0.4 days. Currently, 9.7% of the company’s shares are short sold.
Delcath Systems (DCTH) opened at 0.1359 on Thursday. Delcath Systems has a one year low of $0.02 and a one year high of $6.49. The company’s 50 day moving average price is $0.15 and its 200-day moving average price is $0.15. The company’s market cap is $16.10 million.
A hedge fund recently raised its stake in Delcath Systems stock. Renaissance Technologies LLC raised its position in shares of Delcath Systems, Inc. (NASDAQ:DCTH) by 167.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 160,128 shares of the medical device company’s stock after buying an additional 100,214 shares during the period. Renaissance Technologies LLC owned about 7.29% of Delcath Systems worth $147,000 as of its most recent filing with the SEC. 0.51% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Delcath Systems, Inc. (NASDAQ:DCTH) Short Interest Update” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/07/27/delcath-systems-inc-nasdaqdcth-short-interest-update.html.
About Delcath Systems
Delcath Systems, Inc is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS).
Receive News & Ratings for Delcath Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems Inc. and related companies with MarketBeat.com's FREE daily email newsletter.